Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Universitätsklinikum Hamburg-Eppendorf
Therapeutic Advances in Childhood Leukemia Consortium
Beth Israel Deaconess Medical Center
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
New York Medical College
St. Jude Children's Research Hospital
Memorial Sloan Kettering Cancer Center
St. Jude Children's Research Hospital
Sanofi
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Therapeutic Advances in Childhood Leukemia Consortium
University of California, San Diego
Medical College of Wisconsin
M.D. Anderson Cancer Center
OHSU Knight Cancer Institute
Milton S. Hershey Medical Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Gruppo Italiano Malattie EMatologiche dell'Adulto
Wake Forest University Health Sciences
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
St. Jude Children's Research Hospital
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
SWOG Cancer Research Network
UNC Lineberger Comprehensive Cancer Center
Massachusetts General Hospital
Wake Forest University Health Sciences
Children's Oncology Group
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
New York Medical College
Betta Pharmaceuticals Co., Ltd.
Sanofi
FDA Office of Orphan Products Development
SWOG Cancer Research Network
University Hospital, Lille
National Cancer Institute (NCI)
Sanofi
Sanofi
Sanofi
Sanofi
Texas Oncology Cancer Center